Search and filter

Analytics dashboards for environmental scans and forecasting bring together structured and unstructured information on payers, competitors, policy, pricing and utilisation to support pharmaceutical access decision-making.

The Beneluxa Initiative on Pharmaceutical Policy is a multi-country horizon scanning, HTA and pricing and reimbursement collaboration between Belgium, the Netherlands, Luxembourg, Austria and Ireland.

The Heads of Medicines Agencies (HMA) is a collaborative network comprising the heads of National Competent Authorities (NCAs) responsible for regulating medicinal products for human and veterinary use within the European Economic Area (EEA).

Horizon scanning is a collaborative and systematic process aimed at identifying new and emerging health technologies, particularly medicines, to ensure the NHS is well-prepared for their introduction, both organisationally and financially. It is carried out separately by the different member nations of the UK - this briefing covers the process followed in England.

The Scottish Medicines Consortium horizon scanning process plays an important role in providing NHS Scotland with intelligence on forthcoming medicines.

The International Horizon Scanning Initiative (IHSI) is a collaborative endeavour among several European countries, established to enhance the anticipation and management of emerging pharmaceutical innovations. Its primary objective is to equip healthcare decision-makers with comprehensive data on forthcoming medicinal products, thereby facilitating informed policy development and negotiation strategies.

Policy and horizon scanning tools are structured systems and services that monitor emerging developments in health policy, reimbursement frameworks and pharmaceutical pipelines across jurisdictions.

Spain’s horizon scanning for pharmaceuticals is led centrally, but it is designed to support joint planning with the Autonomous Communities. The output is used to sequence early national evaluation work and to help payers plan capacity and budgets ahead of expected launches and new indications.